COVID-19: what has been learned and to be learned about the novel coronavirus disease

The outbreak of Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has thus far killed over 3,000 people and infected over 80,000 in China and elsewhere in the world, resulting in catastrophe for humans. Similar to its homologous virus, SARS-CoV, which caused SARS in thousands of people in 2003, SARS-CoV-2 might also be transmitted from the bats and causes similar symptoms through a similar mechanism. However, COVID-19 has lower severity and mortality than SARS but is much more transmissive and affects more elderly individuals than youth and more men than women. In response to the rapidly increasing number of publications on the emerging disease, this article attempts to provide a timely and comprehensive review of the swiftly developing research subject. We will cover the basics about the epidemiology, etiology, virology, diagnosis, treatment, prognosis, and prevention of the disease. Although many questions still require answers, we hope that this review helps in the understanding and eradication of the threatening disease.

[1]  William A. Lee,et al.  Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys , 2016, Nature.

[2]  Qiang Zhou,et al.  Structure of dimeric full-length human ACE2 in complex with B0AT1 , 2020, bioRxiv.

[3]  H. Doerr,et al.  Stability and inactivation of SARS coronavirus , 2004, Medical Microbiology and Immunology.

[4]  A. Ahuja,et al.  Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. , 2005, Radiology.

[5]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[6]  Hanxiong Guan,et al.  Imaging changes in patients with 2019-nCov , 2020, European Radiology.

[7]  M. Jackson,et al.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings , 2007, American Journal of Infection Control.

[8]  Jue Fan,et al.  Specific ACE2 Expression in Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection , 2020, bioRxiv.

[9]  Y. Hu,et al.  On the use of corticosteroids for 2019-nCoV pneumonia , 2020, The Lancet.

[10]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[11]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[12]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[13]  Y. Guan,et al.  Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? , 2002, The Lancet.

[14]  E. Decroly,et al.  Insights into RNA synthesis, capping, and proofreading mechanisms of SARS-coronavirus , 2014, Virus Research.

[15]  W. Silverstein,et al.  First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia , 2020, The Lancet.

[16]  Chong-Jen Yu,et al.  Clinical Manifestations, Laboratory Findings, and Treatment Outcomes of SARS Patients , 2004, Emerging infectious diseases.

[17]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[18]  J. Druce,et al.  A quantitative assessment of the efficacy of surgical and N95 masks to filter influenza virus in patients with acute influenza infection. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  Catharine I Paules,et al.  Coronavirus Infections-More Than Just the Common Cold. , 2020, JAMA.

[20]  P. Niu,et al.  Ultrapotent Human Neutralizing Antibody Repertoires Against Middle East Respiratory Syndrome Coronavirus From a Recovered Patient , 2018, The Journal of infectious diseases.

[21]  C. Ruppert,et al.  Surfactant alteration and replacement in acute respiratory distress syndrome , 2001, Respiratory research.

[22]  Jing Zhao,et al.  Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia , 2020, The New England journal of medicine.

[23]  Xin Li,et al.  The clinical pathology of severe acute respiratory syndrome (SARS): a report from China , 2003, The Journal of pathology.

[24]  P. Vollmar,et al.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany , 2020, The New England journal of medicine.

[25]  W. Lu,et al.  ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection , 2020, medRxiv.

[26]  R. Harley,et al.  Differential role for T cells in the development of fibrotic lesions associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia versus Acute Respiratory Distress Syndrome. , 2003, American journal of respiratory cell and molecular biology.

[27]  K. Kedzierska,et al.  Suppressor of Cytokine Signaling 4 (SOCS4) Protects against Severe Cytokine Storm and Enhances Viral Clearance during Influenza Infection , 2014, PLoS pathogens.

[28]  S. Grupp,et al.  Current concepts in the diagnosis and management of cytokine release syndrome. , 2014, Blood.

[29]  Z. Memish,et al.  Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy , 2013, International Journal of Infectious Diseases.

[30]  I. Khalid,et al.  Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital , 2016, Annals of thoracic medicine.

[31]  R. Duval,et al.  Human Coronaviruses: Insights into Environmental Resistance and Its Influence on the Development of New Antiseptic Strategies , 2012, Viruses.

[32]  Michael G. Katze,et al.  Into the Eye of the Cytokine Storm , 2012, Microbiology and Molecular Reviews.

[33]  Ziding Zhang,et al.  Isolation and Characterization of 2019-nCoV-like Coronavirus from Malayan Pangolins , 2020, bioRxiv.

[34]  Ji’an Pan,et al.  SARS-CoV nucleocapsid protein antagonizes IFN-β response by targeting initial step of IFN-β induction pathway, and its C-terminal region is critical for the antagonism , 2010, Virus Genes.

[35]  B. Na,et al.  Clinical and Laboratory Findings of Middle East Respiratory Syndrome Coronavirus Infection. , 2019, Japanese journal of infectious diseases.

[36]  H. Einsele,et al.  Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  E. Dong,et al.  An interactive web-based dashboard to track COVID-19 in real time , 2020, The Lancet Infectious Diseases.

[38]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[39]  Y. Waheed,et al.  The World after Ebola: An Overview of Ebola Complications, Vaccine Development, Lessons Learned, Financial Losses, and Disease Preparedness. , 2019, Critical reviews in eukaryotic gene expression.

[40]  Lisa E. Gralinski,et al.  Molecular pathology of emerging coronavirus infections , 2014, The Journal of pathology.

[41]  P. Horby,et al.  A novel coronavirus outbreak of global health concern , 2020, The Lancet.

[42]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[43]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[44]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[45]  P. Yip,et al.  A revisit on older adults suicides and Severe Acute Respiratory Syndrome (SARS) epidemic in Hong Kong , 2008, International journal of geriatric psychiatry.

[46]  Cheng-wei Lu,et al.  2019-nCoV transmission through the ocular surface must not be ignored , 2020, The Lancet.

[47]  C. Gomersall,et al.  Protecting healthcare staff from severe acute respiratory syndrome: filtration capacity of multiple surgical masks , 2005, Journal of Hospital Infection.

[48]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[49]  J. Baillie,et al.  Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury , 2020, The Lancet.

[50]  Alimuddin Zumla,et al.  Coronaviruses — drug discovery and therapeutic options , 2016, Nature Reviews Drug Discovery.

[51]  R. L. Roper,et al.  SARS vaccines: where are we? , 2009, Expert review of vaccines.

[52]  Tiina Reponen,et al.  Do N95 respirators provide 95% protection level against airborne viruses, and how adequate are surgical masks? , 2006, American journal of infection control.

[53]  憲 大久保 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007 , 2008 .

[54]  Jianhong Wu,et al.  Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions , 2020, Journal of clinical medicine.

[55]  Xiao-Ping Dong,et al.  Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. , 2003, Biomedical and environmental sciences : BES.

[56]  Wei Liu,et al.  Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China , 2020, medRxiv.

[57]  D. Swerdlow,et al.  Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014 , 2016, The American Journal of Pathology.

[58]  Ping Chen,et al.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission , 2020, Science China Life Sciences.

[59]  T. Su,et al.  Prevalence of psychiatric morbidity and psychological adaptation of the nurses in a structured SARS caring unit during outbreak: A prospective and periodic assessment study in Taiwan , 2006, Journal of Psychiatric Research.

[60]  P. Heeger,et al.  Molecules Great and Small: The Complement System. , 2015, Clinical journal of the American Society of Nephrology : CJASN.

[61]  I. Todorov,et al.  HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen , 2008, Proceedings of the National Academy of Sciences.

[62]  Fei Deng,et al.  Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin , 2020, bioRxiv.

[63]  Hans Anton Schlößer,et al.  Cytokine release syndrome , 2018, Journal of Immunotherapy for Cancer.

[64]  S. Perlman,et al.  Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology , 2017, Seminars in Immunopathology.

[65]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[66]  Lisa E. Gralinski,et al.  Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses , 2017, Science Translational Medicine.

[67]  Y Chow Consensus document on the epidemiology of SARS , 2003 .

[68]  Linqi Zhang,et al.  Antibodies and vaccines against Middle East respiratory syndrome coronavirus , 2019, Emerging microbes & infections.

[69]  T. Velavan,et al.  The COVID‐19 epidemic , 2020, Tropical medicine & international health : TM & IH.

[70]  A. Arvey,et al.  GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses , 2017, Scientific Reports.

[71]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of medical virology.

[72]  C. D. Dela Cruz,et al.  Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. , 2020, JAMA.

[73]  Christian Drosten,et al.  Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group , 2020, bioRxiv.

[74]  K. To,et al.  Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan , 2020, Emerging microbes & infections.

[75]  S. Lo,et al.  A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster , 2020, The Lancet.

[76]  X. Hua,et al.  Modulation of murine dendritic cell function by adenine nucleotides and adenosine: Involvement of the A2B receptor , 2008, European journal of immunology.

[77]  Shan-Chwen Chang Clinical Findings, Treatment and Prognosis in Patients with Severe Acute Respiratory Syndrome (SARS) , 2005, Journal of the Chinese Medical Association.

[78]  Q. Pham,et al.  Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam , 2020, The New England journal of medicine.

[79]  Ling Zhang,et al.  Timely mental health care for the 2019 novel coronavirus outbreak is urgently needed , 2020, The Lancet Psychiatry.

[80]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[81]  Hongzhou Lu,et al.  Drug treatment options for the 2019-new coronavirus (2019-nCoV). , 2020, Bioscience trends.

[82]  B. Murphy,et al.  An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus , 2004, Nature Medicine.

[83]  N. Hong,et al.  Avascular necrosis of bone in severe acute respiratory syndrome , 2004, Clinical Radiology.

[84]  F. Lionnet,et al.  Lactate dehydrogenase in sickle cell disease. , 2016, Clinica chimica acta; international journal of clinical chemistry.

[85]  H. Johnson,et al.  Applications of acute phase reactants in infectious diseases. , 1999, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[86]  Genomic and protein structure modelling analysis depicts the origin and pathogenicity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China , 2020 .

[87]  B. Cowling,et al.  Clinical prognostic rules for severe acute respiratory syndrome in low- and high-resource settings. , 2006, Archives of internal medicine.

[88]  Jie Dong,et al.  Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study , 2020, Chinese medical journal.

[89]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[90]  D. Falzarano,et al.  SARS and MERS: recent insights into emerging coronaviruses , 2016, Nature Reviews Microbiology.

[91]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of Medical Virology.

[92]  Tiantian Han,et al.  Coronavirus infections and immune responses , 2020, Journal of medical virology.

[93]  B. Cowling,et al.  A Comparative Study of Clinical Presentation and Risk Factors for Adverse Outcome in Patients Hospitalised with Acute Respiratory Disease Due to MERS Coronavirus or Other Causes , 2016, PloS one.

[94]  M. Farcet,et al.  Immunoglobulins and virus antibody titers: of past needs, current requirements, and future options , 2018, Transfusion.

[95]  M. Kikkert,et al.  Host Factors in Coronavirus Replication , 2017, Current topics in microbiology and immunology.